Amphastar Pharmaceuticals (NASDAQ:AMPH) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a buy rating in a report released on Friday.

A number of other research firms also recently weighed in on AMPH. Needham & Company LLC reissued a hold rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an overweight rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $49.18 on Friday. Amphastar Pharmaceuticals has a 12 month low of $36.56 and a 12 month high of $65.92. The company has a market cap of $2.41 billion, a P/E ratio of 17.02, a P/E/G ratio of 0.85 and a beta of 0.82. The business’s 50 day moving average is $44.56 and its two-hundred day moving average is $42.61. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. The firm had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. On average, equities analysts expect that Amphastar Pharmaceuticals will post 3.71 EPS for the current year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the transaction, the director now directly owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now directly owns 33,971 shares in the company, valued at $1,463,130.97. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Rong Zhou sold 4,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,979 shares of company stock valued at $1,671,307. 27.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AMPH. Principal Securities Inc. acquired a new stake in Amphastar Pharmaceuticals during the 4th quarter worth approximately $34,000. YHB Investment Advisors Inc. bought a new position in shares of Amphastar Pharmaceuticals during the first quarter worth about $27,000. Quadrant Capital Group LLC raised its position in Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after buying an additional 223 shares during the last quarter. Innealta Capital LLC bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Finally, Blue Trust Inc. boosted its position in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.